Alnylam Pharmaceuticals (ALNY) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $16.26
- Estimate
- $2.25
- Surprise
- +623.0%
- Revenue (period 2026-09-30)
- $1.46B
- Score at report (before → after)
- 6.7 → 6.7/10
Revenue source: xbrl.
How the report landed
Alnylam Pharmaceuticals (ALNY) beat the $2.25 estimate with adjusted EPS of $16.26 — a large 623.0% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.7/10) to Hold at 6.7/10 after the report.
Coverage in the report window
- This Honeywell Aerospace Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday — benzinga, 2026-10-30
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALNY Hold at 6.7/10.
2 of the last 4 quarters beat the estimate; this quarter's +623.0% surprise compares with a +156.9% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Leverage penalty (D/E 2.2): -1.5
- Consecutive earnings misses (2)
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $174.00
- Price target
- $331.00
- Stop
- $167.14
- Upside to target
- +90.2%
- Reward-to-risk
- 6.9:1
The stock trades at 29.3× trailing but 14.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 22 — a level conventionally read as oversold; trading volume is running 6.2× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
ALNY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $23.28B
- P/E (fwd)
- 14.4
- P/E (ttm)
- 29.3
- 52-week range
- $172.31–$479.79
- Off 52-week high
- 63.7%
- RSI (14)
- 22
- Volume vs avg
- 6.21×
- Score today
- 6.7/10